UT Southwestern Medical Center Simmons Comprehensive Cancer Center

哈罗德C。西蒙斯综合癌症中心（SCCC）是国家癌症研究所（NCI）- UT西南医学中心（UTSW）及其卫生系统附属机构的指定癌症中心， 帕克兰健康与医院系统和达拉斯儿童医疗中心。SCCC的使命是缓解 通过突破性发现、跨学科研究和有影响力的社区， 参与、教育和卓越的患者护理。卡洛斯L. Arteaga，医学博士，肩负着UTSW癌症活动的权威，并为该中心重新塑造了一个愿景， 将科学转化为UTSW整体使命的前沿。为了实现这一目标，SCCC战略 《2020-2025年计划》优先考虑增加以癌症为重点的资金和对临床试验的基础设施支持， 通过进一步发展多学科癌症护理，扩大癌症治疗的临床能力， 新的> 300，000平方英尺。门诊癌症护理塔，并重新强调社区外展， 订婚此外，SCCC将继续创造教育和培训机会， 赋予新一代的基础科学家，医生科学家，临床研究人员和其他医疗保健 提供者在癌症发现、临床研究和护理、癌症控制和社区方面发挥作用 外展该中心的运作是通过一个有远见的和高素质的高级领导团队优化 和创造价值的行政基础设施。领导力、基础设施和一个积极参与的中心 227名科学家和临床研究人员组成了五个高度互动的研究小组。 细胞网络在癌症，发展和癌症，化学和癌症，实验 治疗学、人口科学和癌症控制。在目前的六年供资周期内，SCCC已 获得了几个大型合作多研究者奖项，包括一个新的肾癌SPORE，六个新的 U 01，和两个新的U 54，并保持两个NCI资助的T32。由于加强了临床试验， 在基础设施方面，干预性临床试验的应计费用增加了一倍以上。快速的发现和 有效转化研究的发展得到六个共享资源的支持：生物统计学，数据 科学，高通量筛选，活细胞成像，小动物成像和组织管理。今天， SCCC每年获得2500万美元的NCI直接资助。它成功地利用了癌症中心支持赠款 （CCSG）的资金在本期间继续中心的快速增长，如 招募97名新成员。SCCC自2014年（六年）以来已投资2.1亿美元，并已获得另一笔投资。 在未来五年，机构承诺提供2.32亿美元，以扩大可用资源的范围。这些 令人印象深刻的发展确保了集水区的需求和关注得到解决， 将继续他们在推进癌症生物学的理解方面的模范记录，同时将这些 随着癌症控制、诊断和治疗新方法的发展，这些发现也得到了证实。

The Harold C. Simmons Comprehensive Cancer Center (SCCC) is the National Cancer Institute (NCI)- designated cancer center of the UT Southwestern Medical Center (UTSW) and its health system affiliates, Parkland Health & Hospital System, and Children’s Medical Center of Dallas. SCCC’s mission is to ease the burden of cancer through ground-breaking discovery, transdisciplinary research, impactful community engagement, education, and exceptional patient care. Upon arrival as the new Director in 2017, Carlos L. Arteaga, MD, shouldered authority over UTSW cancer activities and recasted a vision for the Center that focuses on the translation of science into the forefront of UTSW’s overall mission. To accomplish this, the SCCC Strategic Plan 2020-2025 prioritizes an increase in cancer-focused funding and infrastructure support for clinical trials, expansion of the clinical capacity for cancer treatment through further developed multidisciplinary cancer care, a new > 300,000 sf. Outpatient Cancer Care Tower, and a renewed emphasis on community outreach and engagement. In addition, SCCC will continue to create educational and training opportunities aimed at empowering a new generation of basic scientists, physician-scientists, clinical investigators, and other healthcare providers to make a difference in cancer discovery, clinical investigation and care, cancer control, and community outreach. The Center’s operations are optimized through a visionary and highly qualified Senior Leadership team and a value-creating administrative infrastructure. Together, leadership, infrastructure, and an engaged Center membership of 227 scientists and clinical investigators are organized into five highly interactive research programs—Cellular Networks in Cancer, Development and Cancer, Chemistry and Cancer, Experimental Therapeutics, and Population Science and Cancer Control. During the current six-year funding cycle, SCCC has secured several large collaborative multi-investigator awards, including a new SPORE in kidney cancer, six new U01s, and two new U54s, and maintains two NCI-funded T32s. As a result of strengthening the clinical trials infrastructure, accruals to interventional clinical trials has more than doubled. The rapid pace of discovery and movement toward effective translational research is supported by six shared resources: Biostatistics, Data Science, High Throughput Screening, Live Cell Imaging, Small Animal Imaging, and Tissue Management. Today, SCCC has $25M in annual direct NCI funding. It has successfully leveraged Cancer Center Support Grant (CCSG) funding during the current period to continue the rapid growth of the Center, as demonstrated by the recruitment of 97 new members. SCCC has invested $210M since 2014 (six years) and has secured another $232M in institutional commitment for the next five years to increase the range of available resources. These impressive developments ensure that catchment area needs and concerns are addressed and SCCC scientists will continue their exemplary track record in advancing understanding of cancer biology while coupling these findings with the development of novel approaches to cancer control, diagnosis, and treatment.